Multicenter, Open-Label Phase II Study of Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
Phase of Trial: Phase II
Latest Information Update: 27 Nov 2016
At a glance
- Drugs Regorafenib (Primary)
- Indications Haemangiosarcoma
- Focus Therapeutic Use
- 30 Apr 2014 New source identified and integrated (Robert H. Lurie Comprehensive Cancer Center, Northwestern University).
- 17 Mar 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 10 Feb 2014 New trial record